GLP-1: New Metrics, New Molecules, New Prices Topics We Cover: 00:00 New data from Harvard/Mass General may classify nearly 70% of adults as having obesity 03:00 A new oral triple agonist shows record-setting absorption rates 07:00 Fractal Healths Revita procedure: weight maintenance after stopping GLP-1s 12:00 Zepbound vial prices drop (full breakdown by dose) 16:00 Daves personal experience switching off Mounjaro and intense hunger return 22:00 Novo Nordisks EVOKE/EVOKE+ Alzheimers trial: what the data really means 29:00 Why GLP-1 neurological research is just getting started 33:00 Updates on access, partners, and major news coming soon for Medicare patients If youre on Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, or compounded versions, this episode gives you the insight and context you need to have more competent and confident conversations with your doctor
If you have a deficiency in the G6PD enzyme, it can be unsafe to administer doses of Vitamin C above 10g
Since then, several GLP-1s for obesity have been approved for new indications, such as secondary cardiovascular risk reduction (Wegovy), sleep apnea (Zepbound) and metabolic dysfunction-associated steatohepatitis, or MASH (Wegovy)
Rybelsus Rybelsus, the oral tablet form of semaglutide, expires two years from the date of manufacture
A medication that may work for a family member or a friend may not be the ideal medication for you